News | February 19, 2025
Merck’s Welireg receives European approval for two indications
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Merck has also decided to end the favezelimab clinical development program
Subscribe To Our Newsletter & Stay Updated
